{
    "nct_id": "NCT00285025",
    "title": "A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2006-01-31",
    "description_brief": "The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison to placebo, decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate AD.\n\nSecondary objectives are to assess the effect of SR57667B on functional decline and its safety/tolerability in patients with mild to moderate AD, and to document plasma concentrations of SR57667 in patients with mild to moderate AD.",
    "description_detailed": "Multinational, multicenter, randomized, parallel-group, double-blind, phase II study",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "SR57667B (paliroden)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests SR57667B (4 mg/day vs placebo) to reduce cognitive and global clinical decline over 1 year in mild\u2013moderate AD, which aims to alter disease course rather than only treat a behavioral symptom. The listed intervention and objectives are from the trial registry. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Identification \u2014 SR57667B is the small-molecule investigational drug paliroden (SR57667). Paliroden is described in drug databases and vendor/product pages as an orally active, non-peptidic neurotrophic compound that activates synthesis of endogenous neurotrophins / has neuroprotective/neurotrophic activity (and has also been described with possible MAO-B activity in some sources). Because it is a small molecule with a putative neurotrophic/neuroprotective mechanism intended to slow progression, it fits the definition of a disease-targeted small molecule rather than a purely symptomatic cognitive enhancer or a biologic. \ue200cite\ue202turn0search11\ue202turn1search0\ue202turn1search2\ue201",
        "Reflect: The trial primary endpoints are cognitive and global clinical decline (symptom outcomes), which might suggest a symptomatic effect; however the drug\u2019s described mechanism (neurotrophic / neuroprotective) implies an attempt at disease modification. Given SR57667B is a small chemical entity (not a biologic) and was developed to affect underlying neuronal survival/neurotrophic processes, the best category is 'disease-targeted small molecule.' Development was later discontinued for insufficient efficacy, consistent with historical trial reporting. \ue200cite\ue202turn1search1\ue202turn0search9\ue201",
        "Web-search sources used (key hits): 1) Trial registry entry for the Phase II AD study (SR57667B; objectives, dose 4 mg/day, placebo comparator). \ue200cite\ue202turn0search1\ue202turn0search5\ue201 2) Clinical-trial registry/ICH-GCP summary pages listing the same study details and sponsor (Sanofi). \ue200cite\ue202turn0search9\ue202turn2search5\ue201 3) Drug/reference pages identifying SR57667B as paliroden, describing chemical name, neurotrophic/neuroprotective activity, and development history. \ue200cite\ue202turn0search11\ue202turn1search2\ue202turn1search0\ue201",
        "Notes / ambiguity: The trial measures cognitive decline (a symptomatic outcome) which can blur the boundary between a symptomatic cognitive enhancer and a disease-modifying agent. Because the intervention is a small-molecule neurotrophic agent intended to promote neuronal survival/repair (disease-modifying mechanism) rather than a monoclonal antibody/vaccine or a pure neurotransmitter reuptake modulator used only for symptomatic benefit, I classified it as 'disease-targeted small molecule.' If you prefer a stricter rule that any drug whose primary endpoint is symptomatic cognitive benefit should be labeled 'cognitive enhancer', say so and I will reclassify. \ue200cite\ue202turn0search1\ue202turn1search0\ue201"
    ],
    "agent_type": "E) Neurogenesis",
    "explanation_agent": [
        "Reason: The trial tests SR57667B (paliroden) \u2014 a small-molecule, orally active compound described in drug references and the trial registry as a neurotrophic/neuroprotective agent that activates synthesis of endogenous neurotrophins and promotes neurogenesis. The study objective is to slow cognitive/global decline over 1 year in mild\u2013moderate AD, consistent with an attempt at disease modification via neurotrophic/neurogenic mechanisms. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Act: Extracted details \u2014 SR57667B (paliroden) is listed as the investigational drug in the Phase II AD study (4 mg/day vs placebo) sponsored by Sanofi. Drug databases and product summaries describe SR57667B/paliroden as a non-peptidic neurotrophic compound that increases endogenous neurotrophin synthesis and stimulates neurogenesis; some sources also note possible MAO\u2011B inhibitory activity as an additional/uncertain property. Based on the primary biological focus (neurotrophic activity and promotion of neurogenesis/neuron survival), the most specific CADRO match is E) Neurogenesis. \ue200cite\ue202turn0search1\ue202turn0search6\ue202turn0search7\ue201",
        "Reflect: The drug\u2019s described neurotrophic/neuroprotective mechanism overlaps conceptually with synaptic plasticity/neuroprotection (CADRO M). However, because multiple primary sources emphasize activation of endogenous neurotrophins and effects on adult neurogenesis, E) Neurogenesis is the most specific fit. If one prioritized a broader neuroprotection label instead, M) Synaptic Plasticity/Neuroprotection would be an alternative; but given the available mechanistic descriptions I confirm E) Neurogenesis as the best classification. \ue200cite\ue202turn0search6\ue202turn0search7\ue201",
        "Web search results used: Trial entry showing SR57667B (paliroden) Phase II AD study and dose/objectives; MedPath/clinical-trial listing. \ue200cite\ue202turn0search1\ue201",
        "Drug/mechanism references: DrugBank entry and product/reagent pages describing paliroden as an orally active neurotrophic compound that activates endogenous neurotrophin synthesis and stimulates neurogenesis; some sources note possible MAO\u2011B inhibition. \ue200cite\ue202turn0search6\ue202turn0search2\ue201"
    ]
}